牛牛AI助理已提取核心訊息
Andrew Obenshain, President and CEO of bluebird bio, Inc., completed a sale of 1,879 shares of common stock on February 5, 2024. The transaction was carried out in the open market with a sale price of $0.9025 per share, resulting in a total value of approximately $1,695.80. Following the sale, Obenshain's direct holdings in the company amount to 286,093 shares of common stock.
Andrew Obenshain, President and CEO of bluebird bio, Inc., completed a sale of 1,879 shares of common stock on February 5, 2024. The transaction was carried out in the open market with a sale price of $0.9025 per share, resulting in a total value of approximately $1,695.80. Following the sale, Obenshain's direct holdings in the company amount to 286,093 shares of common stock.
藍鳥生物公司總裁兼首席執行官安德魯·奧本沙因於2024年2月5日完成了1,879股普通股的出售。該交易在公開市場上進行，出售價格爲每股0.9025美元，總價值約爲1,695.80美元。出售後，Obenshain在該公司的直接持有量爲286,093股普通股。
藍鳥生物公司總裁兼首席執行官安德魯·奧本沙因於2024年2月5日完成了1,879股普通股的出售。該交易在公開市場上進行，出售價格爲每股0.9025美元，總價值約爲1,695.80美元。出售後，Obenshain在該公司的直接持有量爲286,093股普通股。
有用
沒用